The world of oncology is constantly evolving, and the role of PD-L1 CPS in gastric cancer treatment is a hot topic. But is it a reliable indicator for immunotherapy? The answer is not so straightforward.
Dr. Yelena Y. Janjigian led an insightful discussion on this very subject, focusing on the NCCN's guidelines for advanced esophageal and gastric cancers. The guidelines suggest adding immune checkpoint inhibitors for patients with a PD-L1 combined positive score (CPS) of at least 1, but the preference is given when CPS is 5 or higher. This leaves a gray area for patients with CPS between 1 and 5, sparking a debate among experts.
But here's where it gets controversial: Dr. Janjigian argues that PD-L1 scores are not always reliable, and retesting is often necessary. She highlights a case where a patient's PD-L1 status was initially negative but later found to be positive, showcasing the potential variability in testing. This raises the question: How much faith should we put in PD-L1 CPS scores?
The discussion delved into various scenarios, including patients with low CPS scores and the real-world benefits they experience. The panel also explored the limitations of CPS scoring in guiding first-line therapy and its impact on clinical decision-making. For instance, Dr. Fayez Estefan shared their approach of discussing IO with patients who have a CPS of 1, emphasizing shared decision-making.
A thought-provoking moment: Dr. Janjigian questioned the reliability of PD-L1 testing, citing the controlled environment of clinical trials versus the variability in clinical practice. She argued that in real-world settings, the quality of samples and testing can vary significantly, affecting the accuracy of PD-L1 CPS scores. This led to a discussion on the importance of considering anti–PD-1 therapy, especially when other treatment options are limited.
The conversation also touched on the challenges of managing patients who have not received more than one line of therapy and the significance of using the most effective treatment first. The panel shared their experiences and preferences for second-line treatments, such as taxanes with ramucirumab. Additionally, they discussed the use of nivolumab in liver metastases and the potential benefits of retesting or rebiopsy in cases of PD-L1 heterogeneity.
This engaging roundtable event left attendees with much to consider. The key takeaway? The role of PD-L1 CPS in frontline gastric cancer treatment is complex and controversial. While it provides valuable guidance, the reliability of PD-L1 testing and the interpretation of CPS scores require careful consideration. As the field advances, ongoing discussions like this are crucial to refining treatment strategies and ensuring the best possible outcomes for patients.
What are your thoughts on the reliability of PD-L1 CPS in guiding immunotherapy decisions? Share your opinions and experiences in the comments below, especially if you've encountered similar testing discrepancies. Let's continue the conversation and explore the nuances of this critical aspect of cancer care.
